trial

D-serine for the Schizophrenia Prodrome

NCTId NCT00826202
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 44 (actual)
Sponsored by Nathan Kline Institute for Psychiatric Research
Primary completion 2012-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
44 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2009-03
Primary completion
2012-11
Eligibility
ALL · 13 Years · 35 Years

Interventions & indications

Drugs
D-serine

Sponsors

Nathan Kline Institute for Psychiatric ResearchLead Sponsor
Yale UniversityCollaborator
The Zucker Hillside HospitalCollaborator
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Daniel C. Javitt, MD, PhDPrincipal Investigator

Sites

4 total
New Haven, United StatesGlen Oaks, United StatesNew York, United StatesOrangeburg, United States

Linked catalysts

1
D-serine for the Schizophrenia Prodrome — primary completion2012-11

Facts & assertions

4 sourced
Enrollment
44
Phase
PHASE2
Primary Completion Date
2012-11
Status
COMPLETED
relationships
The graph out of here
drug
D-serine
drug
lead_sponsor
Nathan Kline Institute for Psychiatric Research
company
collaborator
Yale University
company
The Zucker Hillside Hospital
company
indication
Schizophrenia Prodrome
indication
Schizophrenia
indication
investigator
Daniel C. Javitt, MD, PhD
person